<DOC>
	<DOCNO>NCT00527800</DOCNO>
	<brief_summary>This prospective cohort study HIV-infected uninfected child enrol 6 week 9 month age follow age 21 month . All HIV-infected child give trimethoprim-sulfamethoxazole ( TMP-SMX ) prophylaxis 6 week age . HIV-uninfected child bear HIV-infected mother give TMP/SMX prophylaxis duration breastfeed randomize continuation TMP/SMX discontinuation TMP/SMX prophylaxis . HIV-uninfected child bear HIV-uninfected mother give TMP/SMX prophylaxis . Study participant follow health care need designate study clinic . All mother-child pair receive basic care package include insecticide-treated bednets ( ITNs ) enrollment . All HIV-infected mother child receive antiretroviral therapy eligible accord standardized World Health Organization ( WHO ) criterion . Study participants 4 month age old least 5 kg randomize treatment artemether-lumefantrine ( AL ) dihydroartemisinin-piperaquine ( DP ) time first diagnosis uncomplicated malaria . Study participant receive antimalarial treatment regimen future episode uncomplicated malaria . Study participant less 4 month age le 5 kg diagnose malaria episode complicate malaria treat quinine accordance local guideline . The investigator test hypothesis : 1 . TMP/SMX prophylaxis highly effective prevent malaria HIV-infected HIV-uninfected child 2 . The use TMP/SMX prophylaxis associate increase risk infection malaria parasites contain antifolate resistance-conferring mutation . 3 . The use antiretroviral ( ARV ) drug associate decreased incidence malaria . 4 . The efficacy , safety , tolerability AL DP treatment uncomplicated malaria differ . In 2008 , receive approval fund extend trial 2012 . We follow child 5 year age . First randomization continue discontinue TMP/SMX prophylaxis HIV-exposed population occur 6-8 week cessation breastfeed HIV status confirm negative DNA PCR . A second randomization occur 2 year age HIV-exposed participant . At point HIV-exposed child originally randomize continue TMP/SMX prophylaxis randomize either immediately discontinue TMP/SMX prophylaxis continue prophylaxis age 4 year . All child TMP/SMX 4 5 year age . We also add additional hypothesis test study extension : 5 . Prolonged TMP/SMX prophylaxis result increase incidence malaria child year immediately follow cessation prophylaxis compare child use prophylaxis year never prophylaxis .</brief_summary>
	<brief_title>Interactions Between HIV Malaria African Children</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<criteria>1 . Age 6 week 9 month 2 . Documented HIV1 status mother child 3 . Agreement come study clinic febrile episode illness 4 . Agreement avoid medication administer outside study protocol 5 . Guardian age 18 year old ( age limit parent ) 6 . Parent guardian willing provide inform consent 7 . Residence within 30 km radius study clinic 1 . HIVexposed infant already stop receive TMP/SMX result stop breastfeed test HIVnegative screen 2 . Intention move 30 km study clinic followup period 3 . History allergy sensitivity AL DP TMP/SMX 4 . Active medical problem require inpatient evaluation time screen</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>9 Months</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Malaria</keyword>
	<keyword>HIV</keyword>
	<keyword>Trimethoprim-sulfamethoxazole</keyword>
	<keyword>Artemether-lumefantrine</keyword>
	<keyword>Dihydroartemisinin-piperaquine</keyword>
	<keyword>Acute Infection</keyword>
</DOC>